These findings show comparable rates of JAK2, CALR and MPL-mutations as recently published in a large dataset of 2035 MPN patients (Grinfeld et al. 2018), including patients with PV and MPN-U. This evidence concerns the gene MPL and myeloproliferative neoplasm.